Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Collegium Pharmaceutical reports record 2022 performance and outlines growth strategies

Collegium Pharmaceutical's strong 2022 performance and strategic acquisitions position it for continued success in 2023 with a focus on growth.
The company's commercial strengths in key products like BELBUCA and Xtampza ER drive revenue and showcase growth potential.
Challenges in managing leverage, accelerating franchise growth, and navigating market dynamics are balanced by opportunities for expansion and innovation.
Analysts' inquiries reflect interest in Collegium Pharmaceutical's strategies, market positioning, and response to regulatory changes for future growth.

Collegium Pharmaceutical reports record Q1 revenue amidst patent challenges

Collegium Pharmaceutical's Q1 2023 performance showcased record revenue and strong financial management strategies.
The company faces challenges from patent infringement risks and generic competition, requiring a focus on defending IP and market positioning.
Opportunities in volume growth, business development, and strategic investments in key products position Collegium for long-term success.
Maintaining a balance between defending IP, managing expenses, and driving growth will be crucial for Collegium's future performance.

Collegium Pharmaceutical posts record revenue and growth, eyes strategic acquisitions

Collegium Pharmaceutical reported strong financial performance in Q2 2023, with a focus on achieving a banner year. Despite challenges with Xtampza ER and growth expectations, the company remains committed to improving access, reducing debt, and returning capital to shareholders.

Collegium Pharmaceutical excels in Q3, eyes growth opportunities ahead

Collegium Pharmaceutical reports strong Q3 2023 performance with record revenue and EBITDA growth, driven by successful contract renegotiations and operational efficiency.
Challenges include mitigating declining scripts, navigating patient profiles, and sustaining growth amidst market uncertainties, requiring strategic adjustments and foresight.
Opportunities lie in Medicare Part D market expansion, differentiated asset focus, and strategic valuations, positioning Collegium for future growth and market leadership.

Collegium Pharmaceutical reports record revenue and strategic wins in pain management market

Collegium Pharmaceutical's Q4 2023 earnings call highlighted exceptional financial achievements, robust product performance, and strategic wins in the pain management market. While facing challenges in maintaining guidance and addressing analyst queries, the company remains optimistic about its future outlook and growth potential.

Collegium Pharmaceutical reports strong Q1 earnings amidst leadership transition

Collegium Pharmaceutical's Q1 2024 earnings call highlighted strong financial performance, leadership transition, and growth strategies.
Despite challenges such as CEO resignation and competitive landscape dynamics, the company remains focused on its market position and growth potential.
Opportunities for business development priorities and strategic partnerships offer avenues for future growth and expansion.

Collegium Pharmaceutical reports record Q3 performance and navigates market challenges

Collegium Pharmaceutical's Q3 performance showcased robust financial results and strategic moves to strengthen their market position. While facing challenges in formulary changes and market competition, the company is well-positioned to leverage opportunities in the ADHD market and drive continued growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Mike Heffernan - Chairman Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Oren Livnat - H.C. Wainwright Operator Greetings.

Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.45 per share, missing the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.32 per share a year ago.

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates

– Generated Q1'24 Net Revenue of $144.9 Million – – Delivered Q1'24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1'24 GAAP Net Income of $27.7 Million vs. Q1'23 GAAP Net Loss of $(17.4) Million – – Delivered Q1'24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year – – Board of Directors Authorized $35.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2024 Guidance – – Conference Call Scheduled for Today at 4:30 p.m.

Collegium Reports First Quarter 2024 Financial Results

Besides Wall Street's top -and-bottom-line estimates for Collegium Pharmaceutical (COLL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics

Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.

Collegium (COLL) to Report Q1 Earnings: Here's What to Expect

STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 (the “Notes”) (CUSIP No. 19459JAA2; ISIN No. US19459JAA25) for redemption on Friday, June 14, 2024 (the “Redemption Date”).

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

AppLovin Corp

EMCOR Group

Kaiser Aluminum

Textron

APP, KALU, COLL, EME and TXT are five stocks with explosive relative price strength.

Time to Get These 5 Top Relative Price Strength Stocks

Collegium Pharmaceutical (COLL) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Collegium Pharmaceutical (COLL) Is a Great Growth Stock

ANI Pharma

Apogee Enterprises

Couchbase

Blue Bird

Gigacloud Tech

NewLake Capital Partners, Inc.

Palomar

LiveRamp Holdings Inc

RADCOM

The prevailing market sentiment is currently fueled by the allure of "The Magnificent 7" and stocks with high upside potential. Over the last 52 weeks, the S&P 500 is up ~28% compared to the S&P Small-Cap index (~+15%). Small-cap stocks present enticing prospects for growth and value for investors willing to capitalize on calculated risks. The S&P 500 P/E is 25x vs. the S&P Small-Cap at 14.8x.

Top 10 Small-Cap Stocks (SA Quant)

Does Collegium Pharmaceutical (COLL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Collegium Pharmaceutical (COLL) is a Great Choice

Honda

Ultrapar Participacoes S.A.

UGP, HMC and COLL made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 29, 2023.

Best Value Stocks to Buy for February 29th

Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q4 Earnings

– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass.

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Collegium Pharmaceutical (COLL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Collegium Pharmaceutical (COLL) Could Beat Earnings Estimates Again

Collegium Pharmaceutical (COLL) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Why Collegium Pharmaceutical (COLL) Stock Might be a Great Pick

Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.

Collegium (COLL) Shares Rise on Financial Outlook for 2024

Collegium Pharmaceutical (COLL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Collegium Pharmaceutical (COLL): Can Its 8.4% Jump Turn into More Strength?

STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue's ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid.

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences:

Collegium to Participate in Upcoming Investor Conferences

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - President and CEO Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Tim Lugo - William Blair Serge Belanger - Needham & Company Les Sulewski - Truist Securities Operator Greetings, and welcome to Collegium Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Call Transcript

– Q3'23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3'23 GAAP Net Income of $20.6 Million vs. Q3'22 GAAP Net Income of $0.5 Million – – Record Q3'23 Adjusted EBITDA of $89.4 Million, Up 19% Year-over-Year – – Received Extension of Nucynta ® Regulatory Exclusivity through July 2026 – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Updated Full Year 2023 Guidance – – Conference Call Scheduled for Today at 4:30 p.m.

News for Collegium Pharmaceutical Stock (COLL)